Intensive‑Phase Dosing Guidelines for Drug‑Susceptible Pulmonary Tuberculosis in Adults

Recommended Daily Doses (2‑month intensive phase)

• For an adult weighing approximately 70 kg, the guideline‑recommended daily doses are: isoniazid 300 mg, rifampin 600 mg, pyrazinamide 2000 mg, and ethambutol 1200 mg. 1

Weight‑Based Dosing Calculations

Isoniazid (H)

• Standard dosing is 5 mg/kg per day with a maximum of 300 mg; therefore a 70‑kg adult receives 300 mg (dose capped). 1
• Intermittent regimens may use 15 mg/kg (maximum 900 mg) administered two or three times weekly. 1

Rifampin (R)

• Standard dosing is 10 mg/kg per day with a maximum of 600 mg; a 70‑kg adult therefore receives 600 mg. 1
• The >50 kg weight band is explicitly assigned a 600 mg daily dose in the guideline. (CDC/Thorax) 3

Pyrazinamide (Z)

• Recommended dose range is 15–30 mg/kg per day, limited in practice to 2000 mg. 1
• For a 70‑kg adult the guideline selects the upper practical limit of 2000 mg daily. 3
• The British Thoracic Society suggests 35 mg/kg (≈2450 mg for 70 kg), but CDC guidelines cap the dose at 2000 mg. (CDC, British Thoracic Society) 4

Ethambutol (E)

• Standard intensive‑phase dose is 15–25 mg/kg per day. 2
• In the 56–75 kg weight band the guideline specifies 1200 mg daily, corresponding to 16.0–21.4 mg/kg.

• Some guidelines advise 25 mg/kg for the first 8 weeks, then 15 mg/kg during continuation therapy. (European Respiratory Journal) 4

Regimen Structure

• The intensive phase lasts 2 months, delivering either 56 daily doses (7 days/week) or 40 doses (5 days/week). 1
• Daily administration is strongly preferred over intermittent dosing. (European Respiratory Journal) 6
• All four drugs should be taken together, ideally as a single daily dose. 1
• Directly observed therapy (DOT) is recommended; DOT can be provided 5 days/week with appropriate dose adjustments. 1

Clinical Considerations

Necessity of Ethambutol

• Ethambutol should be included unless the patient is at very low risk for isoniazid resistance (e.g., HIV‑negative, no prior TB treatment, not a contact of a drug‑resistant case, and residing in a region with <4 % isoniazid resistance). (American Thoracic Society) 2
• In settings where the risk of single‑drug resistance exceeds 2 %, a four‑drug regimen is advised. (European Respiratory Journal) 4

Monitoring Requirements

• Perform baseline visual‑acuity (Snellen) and color‑discrimination (Ishihara) testing before initiating ethambutol. (MMWR) 9
• Query patients monthly about visual disturbances while on ethambutol. (MMWR) 9
• Obtain baseline liver‑function tests (AST, ALT, bilirubin, alkaline phosphatase). (American Thoracic Society) 2
• Obtain baseline serum creatinine and platelet count. (American Thoracic Society) 2

Dose‑Adjustment Guidance for Ethambutol

• Do not reduce the ethambutol dose during the intensive phase; a 15 mg/kg dose carries minimal optic‑toxicity risk, while a 25 mg/kg dose may be more effective in selected situations. (European Respiratory Journal, MMWR) 4
• The weight‑based table dose of 1200 mg for patients in the 56–75 kg band (16.0–21.4 mg/kg) falls within the safe and effective range. (American Thoracic Society) 2

Pyridoxine Supplementation

• Provide pyridoxine (vitamin B6) 25–50 mg daily to all patients receiving isoniazid to prevent peripheral neuropathy. (CDC) 10